New weekly allocations of doses are posted every Tuesday. Beginning the following Thursday, states can begin ordering doses from that week’s new allocation of 1st doses. Beginning two weeks (Pfizer) or three weeks (Moderna) from the following Sunday, states can begin ordering doses from that week’s new allocation of 2nd doses. After doses are ordered by states, shipments begin the following Monday. The entire order may not arrive in one shipment or on one day, but over the course of the week.
Second doses are opened up for orders on Sundays, at the appropriate interval two or three weeks later according to the manufacturer’s label, with shipments occurring after jurisdictions place orders.
Shipments of an FDA-authorized safe and effective COVID-19 vaccine continue to arrive at sites across America. Vaccinations began on December 14, 2020.
The COVID-19 Claims Reimbursement to Health Care Providers and Facilities for Testing, Treatment, and Vaccine Administration for the Uninsured Program provides reimbursements on a rolling basis directly to eligible health care entities for claims that are attributed to the testing, treatment, and or vaccine administration of COVID-19 for uninsured individuals. The program is funded via the:
Families First Coronavirus Response Act (FFCRA) Relief Fund, which includes funds received from the Public Health and Social Services Emergency Fund, as appropriated in the FFCRCA (P.L. 116-127) and the Paycheck Protection Program and Health Care Enhancement Act (P.L. 116-139) (PPPHCEA), which each appropriated $1 billion to reimburse health care entities for conducting COVID-19 testing for the uninsured; and the Provider Relief Fund, which includes funds received from the Public Health and Social Services Emergency Fund, as appropriated in the Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136), which provides $100 billion in relief funds, including to hospitals and other health care entities on the front lines of the COVID-19 response and the PPPHCEA to reimburse health care entities for treating uninsured individuals with a COVID-19 diagnosis.
The PPPHCEA appropriated an additional $75 billion in relief funds and the Coronavirus Response and Relief Supplemental Appropriations (CRRSA) Act (P.L. 116-260) appropriated another $3 billion. Within the Provider Relief Fund, a portion of the funding will be used to support healthcare-related expenses attributable to the treatment of uninsured individuals with COVID-19.
Health care entities that have conducted COVID-19 testing of uninsured individuals for COVID-19 or provided treatment to uninsured individuals with a COVID-19 diagnosis on or after February 4, 2020, can request claims reimbursement through the program electronically and will be reimbursed generally at Medicare rates, subject to available funding.
This dataset represents the list of health care entities who have agreed to the Terms and Conditions and received claims reimbursement for COVID-19 testing of uninsured individuals and/or treatment for uninsured individuals with a COVID-19 diagnosis.
Deaths involving coronavirus disease 2019 (COVID-19), pneumonia, and influenza reported to NCHS by sex and age group and state.
NOTICE TO USERS: As of September 2, 2020, this data file includes the following age groups in addition to the age groups that are routinely included: 0-17, 18-29, 30-49, and 50-64. The new age groups are consistent with categories used across CDC COVID-19 surveillance pages. When analyzing the file, the user should make sure to select only the desired age groups. Summing across all age categories provided will result in double counting deaths from certain age groups.
This dataset shows health conditions and contributing causes mentioned in conjunction with deaths involving coronavirus disease 2019 (COVID-19).
Starting December 23, 2020, the data file will also include the number of deaths that mention the listed conditions. The new column, “COVID-19 Deaths” represents the number of deaths that mention one or more of the conditions indicated. The data file’s existing “Number of Mentions” column represents the number of total conditions mentioned for each age group.
Provisional estimates of selected reproductive indicators. Estimates are presented for: general fertility rates, age-specific birth rates, total and low risk cesarean delivery rates, preterm birth rates and other gestational age categories.
Provisional estimates of selected reproductive indicators from birth data for 2014 through the first quarter of 2016. Estimates are presented for: general fertility rates, age-specific birth rates, total and low risk cesarean delivery rates, preterm birth rates and other gestational age categories.
Provisional estimates of selected reproductive indicators from birth data for 2015 through the third quarter of 2016. Estimates are presented for: general fertility rates, age-specific birth rates, total and low risk cesarean delivery rates, preterm birth rates and other gestational age categories.
NNDSS - TABLE 1MM. Viral hemorrhagic fevers, Crimean-Congo hemorrhagic fever virus to Guanarito virus – 2021. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.
Notice: Due to data processing issues at CDC, data for the following jurisdictions may be incomplete for week 7: Alaska, Arizona, California, Connecticut, Delaware, Florida, Hawaii, Louisiana, Maryland, Michigan, Missouri, North Dakota, New Hampshire, New York City, Oregon, Pennsylvania, and Rhode Island.
This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html.
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published.
NC: Not calculated — There is insufficient data available to support the calculation of this statistic.
Cum: Cumulative year-to-date counts.
Max: Maximum — Maximum case count during the previous 52 weeks.
* Case counts for reporting years 2020 and 2021 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf.
†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
§ Prior to 2015, CDC's National Notifiable Diseases Surveillance System (NNDSS) did not receive electronic data about incident cases of specific viral hemorrhagic fevers; instead data were collected in aggregate as "viral hemorrhagic fevers". NNDSS was updated beginning in 2015 to receive data for each of the viral hemorrhagic fevers listed.